Literature DB >> 22354010

HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFβ activation.

Anne Klotzsche-von Ameln1, Antje Muschter, Markus M Heimesaat, Georg Breier, Ben Wielockx.   

Abstract

A right amount of oxygen and nutrients is essential for a tumor to develop. The role of oxygen dependent pathways and their regulators is therefore of utmost importance although little is known about the detailed impact they can have. Recently we have shown that inhibition of the oxygen sensor PHD2 in tumor cells blocks tumor growth due to the anti-proliferative activity of TGFβ. In this study, we refined these results by comparing different shPHD2 sequences in depth in the early phase of tumor growth. Our findings also reveal an intriguing role for MMP2 and MT1MMP in these settings, as these activated proteases display an anti-proliferative characteristic through the activation of downstream TGFβ targets. In conclusion, PHD2 inhibition is essential for the regulation of the anti-tumoral activity in mouse tumor cells and might bring some new insight in our understanding of tumor growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354010     DOI: 10.4161/cbt.13.4.18830

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  12 in total

Review 1.  Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Authors:  Vaithinathan Selvaraju; Narasimham L Parinandi; Ram Sudheer Adluri; Joshua W Goldman; Naveed Hussain; Juan A Sanchez; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2013-10-31       Impact factor: 8.401

2.  Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer.

Authors:  Xi Ai; Yanhui Wu; Wei Zhang; Zhanguo Zhang; Guannan Jin; Jianping Zhao; Jingjing Yu; Youzhi Lin; Wanguang Zhang; Huifang Liang; Pran K Datta; Mingzhi Zhang; Bixiang Zhang; Xiaoping Chen
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

Review 3.  Genetic modification of hypoxia signaling in animal models and its effect on cancer.

Authors:  J M García-Heredia; B Felipe-Abrio; D A Cano; A Carnero
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

Review 4.  The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation.

Authors:  Silvia Strocchi; Francesca Reggiani; Giulia Gobbi; Alessia Ciarrocchi; Valentina Sancisi
Journal:  Oncogene       Date:  2022-06-15       Impact factor: 8.756

5.  Prolyl 4 hydroxylase: a critical target in the pathophysiology of diseases.

Authors:  Ravi Kant; Anjana Bali; Nirmal Singh; Amteshwar Singh Jaggi
Journal:  Korean J Physiol Pharmacol       Date:  2013-04-10       Impact factor: 2.016

6.  Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection.

Authors:  Li Zhen; Ning Shijie; Zhang Shuijun
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 7.  Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.

Authors:  Jonathan Michael Harnoss; Moritz Johannes Strowitzki; Praveen Radhakrishnan; Lisa Katharina Platzer; Julian Camill Harnoss; Thomas Hank; Jun Cai; Alexis Ulrich; Martin Schneider
Journal:  Hypoxia (Auckl)       Date:  2015-01-30

Review 8.  PHD2: from hypoxia regulation to disease progression.

Authors:  Ana M Meneses; Ben Wielockx
Journal:  Hypoxia (Auckl)       Date:  2016-04-11

Review 9.  Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment.

Authors:  Sundary Sormendi; Ben Wielockx
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

10.  Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis.

Authors:  Chris D Madsen; Jesper T Pedersen; Freja A Venning; Lukram Babloo Singh; Emad Moeendarbary; Guillaume Charras; Thomas R Cox; Erik Sahai; Janine T Erler
Journal:  EMBO Rep       Date:  2015-08-31       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.